CD274 and neoplasm: In the first-line setting, results from the KEYNOTE 024 trial demonstrated that, compared with platinum-based chemotherapy, OS, progression-free survival (PFS), and overall response rate (ORR) were significantly improved in patients with PD-L1 expression on at least 50% of tumor cells and without oncogenic driver mutations [11,12].